Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
PDC*lung
i
Other names:
PDC*lung, PDC*lung01, PDC-LUNG-101, LR19125, LR 19125, LR-19125
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
LG Chem, PDC line Pharma
Drug class:
MUC1 inhibitor, MAGE-A4 inhibitor, NY ESO 1 inhibitor, Survivin inhibitor, MAGE-A3 inhibitor, Melanoma cell surface antigen inhibitor, Multi-MAGE inhibitor
Related drugs:
‹
gatipotuzumab (5)
BTH1704 (0)
AR20.5 (0)
ETBX-061 (0)
GO-203-2c (0)
GT-00A x IL15 (0)
VXL100 (0)
ONT-10 (0)
falimarev/inalimarev (0)
tecemotide (0)
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
TG4010 (0)
afamitresgene autoleucel (3)
IMC-C103C (1)
ADP-A2M4CD8 (1)
CDR404 (0)
IMA201 (0)
IMA401 (0)
KSH01 (0)
MultiTAA T cell therapy (0)
RG6129 (0)
TBI 1201 (0)
TAEST16001 (2)
BNT111 (1)
GSK3377794 (1)
TBI-1301 (1)
CMB305 (0)
GSK2241658A (0)
GSK3845097 (0)
GSK3901961 (0)
ID-LV305 (0)
IDC-G305 (0)
LYL132 (0)
LYL331 (0)
N201 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
PORT-3 (0)
TCRT-ESO-A2 (0)
VTP-600 (0)
CDX-1401 (0)
MVP-S (3)
SVN53-67/M57-KLH peptide vaccine (1)
PC-002 (1)
ABBV-184 (0)
terameprocol (0)
MANA-312 (0)
NEXI-003 (0)
SL-701 (0)
LY2181308 (0)
PDC*mel (0)
gatipotuzumab (5)
BTH1704 (0)
AR20.5 (0)
ETBX-061 (0)
GO-203-2c (0)
GT-00A x IL15 (0)
VXL100 (0)
ONT-10 (0)
falimarev/inalimarev (0)
tecemotide (0)
Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
TG4010 (0)
afamitresgene autoleucel (3)
IMC-C103C (1)
ADP-A2M4CD8 (1)
CDR404 (0)
IMA201 (0)
IMA401 (0)
KSH01 (0)
MultiTAA T cell therapy (0)
RG6129 (0)
TBI 1201 (0)
TAEST16001 (2)
BNT111 (1)
GSK3377794 (1)
TBI-1301 (1)
CMB305 (0)
GSK2241658A (0)
GSK3845097 (0)
GSK3901961 (0)
ID-LV305 (0)
IDC-G305 (0)
LYL132 (0)
LYL331 (0)
N201 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
PORT-3 (0)
TCRT-ESO-A2 (0)
VTP-600 (0)
CDX-1401 (0)
MVP-S (3)
SVN53-67/M57-KLH peptide vaccine (1)
PC-002 (1)
ABBV-184 (0)
terameprocol (0)
MANA-312 (0)
NEXI-003 (0)
SL-701 (0)
LY2181308 (0)
PDC*mel (0)
›
Associations
News
Trials
Filter by
Latest
2ms
PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=73, Active, not recruiting, PDC*line Pharma SAS | Trial primary completion date: Dec 2025 --> Jul 2024
2 months ago
Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
1year
PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=73, Active, not recruiting, PDC*line Pharma SAS | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
1 year ago
Enrollment closed • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
1year
PDC-LUNG-101: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=64, Recruiting, PDC*line Pharma SAS | Trial completion date: Aug 2024 --> Sep 2025 | Trial primary completion date: Aug 2024 --> Sep 2025
1 year ago
Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
over1year
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=64, Recruiting, PDC*line Pharma SAS | Trial primary completion date: Aug 2022 --> Aug 2024
over 1 year ago
Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
4years
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (clinicaltrials.gov)
P1/2, N=64, Recruiting, PDC*line Pharma SAS | Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Nov 2020 --> Aug 2022
4 years ago
Clinical • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
Keytruda (pembrolizumab) • pemetrexed • PDC*lung
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login